Eculizumab in patients with severe coronavirus disease 2019 (COVID-19) requiring continuous positive airway pressure ventilator support: Retrospective cohort study

BACKGROUND: Complement activation contributes to lung dysfunction in coronavirus disease 2019 (COVID-19). We assessed whether C5 blockade with eculizumab could improve disease outcome. METHODS: In this single-centre, academic, unblinded study two 900 mg eculizumab doses were added-on standard therap...

Descripción completa

Detalles Bibliográficos
Autores principales: Ruggenenti, Piero, Di Marco, Fabiano, Cortinovis, Monica, Lorini, Luca, Sala, Silvia, Novelli, Luca, Raimondi, Federico, Gastoldi, Sara, Galbusera, Miriam, Donadelli, Roberta, Mele, Caterina, Piras, Rossella, Noris, Marina, Portalupi, Valentina, Cappelletti, Laura, Carrara, Camillo, Tomatis, Federica, Bernardi, Silvia, Perna, Annalisa, Peracchi, Tobia, Diadei, Olimpia, Benigni, Ariela, Remuzzi, Giuseppe
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2021
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687582/
https://www.ncbi.nlm.nih.gov/pubmed/34928990
http://dx.doi.org/10.1371/journal.pone.0261113

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8687582/
https://www.ncbi.nlm.nih.gov/pubmed/34928990
http://dx.doi.org/10.1371/journal.pone.0261113

Ejemplares similares